Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 2/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21318467 | 0.80 | CLK1 (0.38) | APPMCHR1CLK1DYRK1AGFER | |
| SCHEMBL21835435 | 0.76 | APP (0.49) | APPALOX5KDM4ENPC1RAB9A | |
| SCHEMBL8414545 | 0.74 | KDM4E (0.48) | MIFKDM4ENPC1RAB9AGFER | |
| SCHEMBL22235439 | 0.71 | MCHR1 (0.41) | APPMCHR1KDM4ENPC1RAB9A | |
| SCHEMBL1665528 | 0.71 | RAB9A (0.56) | APPMCHR1KDM4ENPC1RAB9A | |
| SCHEMBL1500181 | 0.71 | PIK3CG (0.55) | APPMCHR1CLK1DYRK1AKDM4E | |
| SCHEMBL5055929 | 0.71 | APP (0.46) | APPMCHR1CLK1DYRK1ANPC1 | |
| SCHEMBL2257095 | 0.69 | APP (0.73) | APPCLK1DYRK1AKDM4ENPC1 | |
| SCHEMBL22259100 | 0.69 | MCHR1 (0.48) | APPMCHR1KDM4ENPC1RAB9A | |
| SCHEMBL31075171 | 0.69 | MCHR1 (0.51) | MCHR1KDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037334-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037334-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037334-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220024915-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024915-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3856194-A2 | INHIBITORS OF VAP-1 | Acucela, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164489-A | Inhibitors of VAP-1 | 奥克塞拉有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020069335-A2 | INHIBITORS OF VAP-1 | ACUCELA INC. (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024915-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | MIF 3688/4885APP 3512/4885MCHR1 3244/4885 |
| US-12037334-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | MIF 3688/4885APP 3512/4885MCHR1 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.